Brief: PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001
19/08/2024 13:11
Aug 19 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER’S SAIRIYO THERAPEUTICS RECEIVES APPROVAL TO
INITIATE
A PHASE 1 HUMAN CLINICAL TRIAL OF PD-001 (REFORMULATED
CEPHARANTHINE)
Source text for Eikon: ID:nGNXbCV5nz
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmadrug
See all newsBrief: PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001
CFRA upgrades AMC, hikes PT to $18 from $2.50
Brief: Lamêlee Amends Definitive Agreement For RTO With Aura Health
Brief: Lamelee Announces Loi For Rto With Aura Health Corp.
Brief: Fancamp Exploration returned to Treasury for cancellation all shares it held of Lamelee